CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have received an average recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Eight ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

On Monday, Catalent Inc (CTLT) stock saw a modest uptick, ending the day at $60.65 which represents a slight increase of $0.20 or 0.33% from the prior close of $60.45. The stock opened at $60.5 and ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

(Reuters) - Catalent (NYSE: CTLT) has agreed to sell its oral drug development and small-scale manufacturing facility in ...

The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms, complementing Ardena's ...

Catalent (CTLT) sells Somerset, NJ facility to Ardena. Corporate headquarters to shift to new location post-transition.

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...